A nanodrug incorporating siRNA PD-L1 and Birinapant for enhancing tumor immunotherapy

Gong, Ting-Ting; Cai, Yujun; Sun, Fengze; Chen, Jiaxin; Su, Zhongzhen; Shuai, Xintao; Shan, Hong

doi:10.1039/d1bm01299a

Cited by 9 publications

(3 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, nanoparticles can be combined with PD-1/ PD-L1 immunotherapy to facilitate tumor immunotherapy. Gong et al 83 developed a cationic liposome containing birinapant and siPD-L1 for the therapy of triple negative breast cancer (TNBC). Birinapant was found to promote CD8+ T cell infiltration and TNF-a secretion in cancers.…”

Section: Immune Checkpoint Inhibitormentioning

confidence: 99%

See 1 more Smart Citation

Immunotherapy: cancer immunotherapy and its combination with nanomaterials and other therapies

Guo¹,

Gao²,

Ahmed³

et al. 2023

J. Mater. Chem. B

View full text Add to dashboard Cite

show abstract

Section: Immune Checkpoint Inhibitormentioning

confidence: 99%

“…Gong et al . 83 developed a cationic liposome containing birinapant and siPD-L1 for the therapy of triple negative breast cancer (TNBC). Birinapant was found to promote CD8+ T cell infiltration and TNF-α secretion in cancers.…”

Section: Immunotherapy Approaches For Tumormentioning

confidence: 99%

Immunotherapy: cancer immunotherapy and its combination with nanomaterials and other therapies

Guo¹,

Gao²,

Ahmed³

et al. 2023

J. Mater. Chem. B

View full text Add to dashboard Cite

show abstract

“…Fe 3 O 4 nanoparticles connected with siPD-L1 (Fe 3 O 4 -siPD-L1) are further coated with microglial membrane (M -BV2 ) to form a biomimetic brain-targeted nanoparticle Fe 3 O 4 -siPD-L1@M -BV2 . After Fe 3 O 4 -siPD-L1@M -BV2 was taken up by orthotopic drug-resistant GBM cells, the disulfide bond between Fe 3 O 4 nanoparticles and siPD-L1 was broken by intracellular GSH, releasing siPD-L1 and inhibiting the protein expression of PD-L1 in orthotopic drug-resistant GBM cells [ 40 ]. Subsequently, T eff cell was activated to enhance the killing effect on drug-resistant GBM cell [ 41 ].…”

Section: Introductionmentioning

confidence: 99%

Biomimetic GBM-targeted drug delivery system boosting ferroptosis for immunotherapy of orthotopic drug-resistant GBM

Liu

Cheng

et al. 2022

J Nanobiotechnol

View full text Add to dashboard Cite

Background Clinical studies have shown that the efficacy of programmed cell death receptor-1/programmed cell death ligand-1 (PD-1/PD-L1) inhibitors on glioblastoma (GBM) is much lower than what is expected because of the low immunogenicity of GBM. Ferroptosis of cancer cells can induce the maturation of dendritic cells (DC cells) and increase the activity of T cell. The activated T cells release IFN-γ, which subsequently induces the ferroptosis of cancer cells. Thus, the aim of this paper is to set up a new GBM-targeted drug delivery system (Fe3O4-siPD-L1@M-BV2) to boost ferroptosis for immunotherapy of drug-resistant GBM. Results Fe3O4-siPD-L1@M-BV2 significantly increased the accumulation of siPD-L1 and Fe2+ in orthotopic drug-resistant GBM tissue in mice. Fe3O4-siPD-L1@M-BV2 markedly decreased the protein expression of PD-L1 and increased the ratio between effector T cells and regulatory T cells in orthotopic drug-resistant GBM tissue. Moreover, Fe3O4-siPD-L1@M-BV2 induced ferroptosis of GBM cells and maturation of DC cell, and it also increased the ratio between M1-type microglia and M2-type microglia in orthotopic drug-resistant GBM tissue. Finally, the growth of orthotopic drug-resistant GBM in mice was significantly inhibited by Fe3O4-siPD-L1@M-BV2. Conclusion The mutual cascade amplification effect between ferroptosis and immune reactivation induced by Fe3O4-siPD-L1@M-BV2 significantly inhibited the growth of orthotopic drug-resistant GBM and prolonged the survival time of orthotopic drug-resistant GBM mice. Graphical Abstract

show abstract

Nanomedicine: Present Perspectives and Future Challenges

Ali,

Sadia,

Tariq

2023

Learning Materials in Biosciences

View full text Add to dashboard Cite

A nanodrug incorporating siRNA PD-L1 and Birinapant for enhancing tumor immunotherapy

Abstract: Triple-negative breast cancer (TNBC) is associated with a worse prognosis and higher mortality than other breast cancers, and intensive efforts are paid to develop therapies targeted to TNBC. TNBC shows...

Cited by 9 publications

References 34 publications

Immunotherapy: cancer immunotherapy and its combination with nanomaterials and other therapies

Immunotherapy: cancer immunotherapy and its combination with nanomaterials and other therapies

Biomimetic GBM-targeted drug delivery system boosting ferroptosis for immunotherapy of orthotopic drug-resistant GBM

Nanomedicine: Present Perspectives and Future Challenges

Contact Info

Product

Resources

About